Antigen binding molecules directed against alppl2 and / or alpp and uses thereof

By designing antigen-binding molecules that specifically bind to ALPPL2 without binding to ALPL or ALPI, the challenge of targeting ALPPL2 cancer cell therapies in existing technologies has been solved, achieving highly efficient killing effects and reducing side effects on normal cells, thus providing a new cancer treatment method.

CN115380050BActive Publication Date: 2026-07-03AGENCY FOR SCI TECH & RES
View PDF 16 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
AGENCY FOR SCI TECH & RES
Filing Date
2021-02-05
Publication Date
2026-07-03

AI Technical Summary

Technical Problem

Current technology lacks effective targeted antibody therapies to treat cancer cells expressing ALPPL2, and conventional antibodies may have side effects on normal cells.

Method used

Develop antigen-binding molecules that specifically bind to ALPPL2 without binding to ALPL or ALPI, including specific amino acid sequence combinations of heavy chain variable regions and light chain variable regions, enhance affinity for ALPPL2 through humanized antibodies, and conjugate with toxins or radioisotopes to enhance killing effects.

Benefits of technology

This study achieved highly efficient targeted killing of ALPPL2-expressing cancer cells, reduced side effects on normal cells, enhanced the killing effects of ADCC and ADC, and provided a new approach for cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115380050B_ABST
    Figure CN115380050B_ABST
Patent Text Reader

Abstract

This invention relates to antigen-binding molecules that specifically bind to ALPPL2 and / or ALPP but not ALPL or ALPI. The invention also relates to pharmaceutical compositions, immunoconjugates, and chimeric antigen receptors comprising said antigen-binding molecules. Furthermore, the invention relates to methods for reducing the expression or activity of ALPPL2 in cancer cells, and methods for treating cancer in subjects.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Identification and engineering of antibodies with variant Fc regions and methods of using same

    US20050037000A1

  • Monovalent antibody fragments useful as therapeutics

    US20080063641A1

  • Single chain FC, methods of making and methods of treatment

    US20080260738A1

  • Reducing interference in ligand-receptor binding assays

    US4737456A

  • Ments

    US544546A